| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399508 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Sep, 2022
(1 year, 11 days ago) | |
| US7977376 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Feb, 2023
(7 months ago) | |
|
US8399508 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Mar, 2023
(6 months ago) | |
|
US7977376 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Aug, 2023
(a month ago) | |
Patanase is owned by Novartis.
Patanase contains Olopatadine Hydrochloride.
Patanase has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Patanase are:
- US8399508
- US7977376
- US8399508*PED
- US7977376*PED
Patanase was authorised for market use on 15 April, 2008.
Patanase is available in spray, metered;nasal dosage forms.
Patanase can be used as allergic rhinitis.
The generics of Patanase are possible to be released after 02 August, 2023.
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2008
Treatment: Allergic rhinitis
Dosage: SPRAY, METERED;NASAL
PATANASE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic